Declan Doogan

Declan Doogan is the founder of Topix Pharmaceuticals, Inc., founded in 1989.
Dr. Doogan is the founder of Juvenescence Therapeutics Ltd., founded in 2020, serving as Director since 2020.
Dr. Doogan was the founder of Portage Pharma Ltd., founded in 2013, served as Chairman from 2013 to 2019.
Dr. Doogan was the founder of Biohaven Pharmaceutical Holding Co. Ltd., founded in 2013, served as Independent Chairman from 2013 to 2021.
Dr. Doogan was the founder of Juvenescence Ltd., founded in 2016, served as Chief Medical Officer & Director.
Current jobs include Chairman at Causeway Therapeutics Ltd., Independent Director at Tenax Therapeutics, Inc. since 2021, Director, Chief Scientific & Clinical Advisor at Celleron Therapeutics Ltd., Director at The Pulmonary Vascular Research Institute, Director at Kleo Pharmaceuticals, Inc. since 2019, Director at BYOMass, Inc. since 2021, Director at Apterna Ltd., and Partner at Mediqventures Ltd.Former jobs include Chief Executive Officer & Chief Medical Officer at Amarin Corp.
Plc, Non-Executive Chairman at Spinifex Pharmaceuticals Pty Ltd. from 2011 to 2012, Chairman at iOx Therapeutics Ltd., Independent Director at Alpha Compute Corp.
from 2019 to 2022, Outside Director at Nxera Pharma Co., Ltd. from 2007 to 2019, Director at Nxera Pharma UK Ltd., Independent Director at Intensity Therapeutics, Inc., Senior VP & Head-Worldwide Development at Pfizer Inc. from 1982 to 2007, Chief Medical Officer & Executive Vice President at Prometheus Laboratories, Inc., Senior Vice President-Head-Worldwide Development at Pfizer (St. Louis), Senior Vice President-Clinical R&D at Pfizer Europe International Ltd., Senior Vice President-Clinical R&D at Pfizer Japan, Inc., Professor at the University of Glasgow School of Medicine, Professor at Kitasato University, and Professor at Harvard T.H.
Chan School of Public Health.
Education includes a doctorate from the University of Glasgow conferred in 1975 and a doctorate from the University of Kent.